LivaNova公共 LIVN 深 滬
已收盤 08-22 16:00:00 美东时间
55.90
+3.040
+5.75%
華盛通- 最 高55.9875
- 今 開53.46
- 成交量 72.80万股
- 最 低 53.40
- 昨 收 52.86
- 總市值 30.48亿
- 52周最高 57.3498
- 市盈率 靜 48.24
- 換手率 1.34%
- 52周最低 32.48
- 委 比 22.26%
- 總股本 5452.57万
- 歷史最高 131.54
- 量 比 1.29
- 振 幅 4.90%
- 歷史最低 23.58
- 每 手 1
- 風險率 5.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $58
Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the price target from $55 to $58.
08-21 22:45
LivaNova shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.
LivaNova shares are trading higher after the company reported better-than-expec...
08-06 23:31
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 0.1% on...
08-06 22:42
LivaNova Raises FY2025 Adj EPS Guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 Est; Raises FY2025 Sales Guidance from $1.316B-$1.341B to $1.353B-$1.366B vs $1.328B Est
LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 analyst estimate. Raises FY2025 sales outlook from $1.316 billion-$1.341 billion to $1.353 billion-$1.366 billion vs $1.328
08-06 18:02
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
LivaNova Shareholders Approve Key Incentive Plans at AGM
LivaNova ( ($LIVN) ) has issued an announcement. On June 11, 2025, LivaNova PLC...
06-12 05:17
LivaNova Initiates Process With U.S. CMS To Seek Reconsideration Of National Medicare Coverage For VNS Therapy In Unipolar Patients With Treatment-Resistant Depression
Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results
06-04 20:12
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
Wolfe Research Upgrades LivaNova to Outperform, Announces $60 Price Target
Wolfe Research analyst Mike Polark upgrades LivaNova (NASDAQ:LIVN) from Peer Perform to Outperform and announces $60 price target.
05-21 00:15
